A Critical Discussion: Possibility of the Strategic Treatment for Various Tumors Using the Leukotriene Receptor Antagonist Based on the Common Pathologic Findings that Mast Cells and Leukotrienes are Involved in the Development and Proliferation of Tumors

One of the antiallergic drugs, the leukotriene receptor antagonist, is indicated with an asthmatic therapeutic drug. We discovered that mast cells and a leukotriene receptor were frequently present in a variety of malignant and benign tumours, proving that the allergic reaction was closely linked to tumour growth and proliferation. We also tested the effectiveness of using a leukotriene receptor antagonist to treat a spontaneous rat tumour and found it to be effective. Our findings indicate that this drug has a broad impact and has less side effects, which may lead to a debate about chemotherapy for the present malignant tumour. The latest evidence and potential prospects in the oncotherapy of the leukotriene receptor antagonist are briefly summarised in this commentary. Combination treatment with leukotriene receptor antagonists alone or other medications is expected to be a potential therapy for tumours. We also hope that preventive medicine will be created to prevent benign tumours from being malignant.

Author (s) Details

Masao Sugamata
Department of Pathology, Tochigi Institute of Clinical Pathology, Japan

View Book :- https://stm.bookpi.org/CTMMR-V13/article/view/733

Leave a Reply

Your email address will not be published. Required fields are marked *